These findings suggest that CRC progression is mediated through the PYK2/GSK-3β(Y216)/β-catenin regulatory axis, ultimately influencing cellular metabolism and contributing to malignant transformation. This evidence concerns the gene PTK2B and colorectal carcinoma.